Alto Neuroscience vs Cue Biopharma, .
Alto Neuroscience vs Cue Biopharma, ., compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Alto Neuroscience is on 43/100 and Cue Biopharma, . on 62/100.
Where each one leads
Alto Neuroscience
- agent readiness: 48/100 against 42/100
- domain rating: 44/100 against 34/100
- headcount: 86 against 38
- funding raised: $370M against $10.0M
- LinkedIn following: 24,482 against 5,297
Cue Biopharma, .
- our overall score: 62/100 against 43/100
At a glance
| Measure | Alto Neuroscience | Cue Biopharma, . |
|---|---|---|
| What it is | Alto Neuroscience is a clinical-stage biopharmaceutical company developing precision psychiatry medicines for mental health conditions. | Developing engineered biologics to harness the immune system for disease treatment. |
| Category | Biotech, MedTech, HealthTech, Drug Discovery | Biotech, Drug Discovery, Immunotherapy, Therapeutics |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Biotech |
| Founded | 2019 | 2017 |
| Headquarters | Los Altos, United States | Boston, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Alto Neuroscience | Cue Biopharma, . |
|---|---|---|
| Employees | 86 | 38 |
| Total funding | $370M | $10.0M |
| Latest round | Registered Direct Offering | Seed |
| LinkedIn followers | 24,482 | 5,297 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Alto Neuroscience | Cue Biopharma, . |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 43/100 | 62/100 |
| Traction | 59/100 | Not published |
| Team | Not published | 60/100 |
| Community | 13/100 | Not published |
| Search visibility | 35/100 | 67/100 |
| Quality | 45/100 | Not published |
| Agent readinessHow well an AI agent can read and act on the site | D (48/100) | D (42/100) |
| Domain ratingLink authority, 0-100 | 44/100 | 34/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Alto Neuroscience | Cue Biopharma, . |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | WordPress | WordPress |
| Frameworks | Jquery | Tailwind CSS |
| Analytics | Google Analytics 4 | Google Analytics 4 |
Alto Neuroscience vs Cue Biopharma, .: common questions
Which is better, Alto Neuroscience or Cue Biopharma, .?
On our 0-100 score Cue Biopharma, . rates higher (62/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do Alto Neuroscience and Cue Biopharma, . compare on the numbers?
Alto Neuroscience leads on agent readiness (48/100 against 42/100), domain rating (44/100 against 34/100), headcount (86 against 38), funding raised ($370M against $10.0M), LinkedIn following (24,482 against 5,297). Cue Biopharma, . leads on our overall score (62/100 against 43/100).
Read the full Alto Neuroscience review and pricing or the Cue Biopharma, . review and pricing. You can also browse other Alto Neuroscience alternatives we track.